Galeatomy: A useful technique aiding high-tension scalp closures. Read more about Galeatomy: A useful technique aiding high-tension scalp closures.
Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes. Read more about Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.
Merkel cell carcinoma: An update and review: Current and future therapy. Read more about Merkel cell carcinoma: An update and review: Current and future therapy.
Atypical features and systemic associations in extensive cases of Grover disease: A systematic review. Read more about Atypical features and systemic associations in extensive cases of Grover disease: A systematic review.
Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis. Read more about Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis.
Plasmacytoid dendritic cells (pDCs) and regulatory T (Treg) cells may be the key to viral reactivation in drug-induced hypersensitivity syndrome (DIHS). Read more about Plasmacytoid dendritic cells (pDCs) and regulatory T (Treg) cells may be the key to viral reactivation in drug-induced hypersensitivity syndrome (DIHS).
Neutrophil-rich subcutaneous fat necrosis of the newborn: A potential mimic of infection. Read more about Neutrophil-rich subcutaneous fat necrosis of the newborn: A potential mimic of infection.
The distribution of cutaneous metastases correlates with local immunologic milieu. Read more about The distribution of cutaneous metastases correlates with local immunologic milieu.
Updates in adult-onset Still disease: Atypical cutaneous manifestations and associations with delayed malignancy. Read more about Updates in adult-onset Still disease: Atypical cutaneous manifestations and associations with delayed malignancy.
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. Read more about Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
